Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Mar;52(3):177–180. doi: 10.1136/jcp.52.3.177

Atypical C-ANCA following high dose intravenous immunoglobulin.

S Jolles 1, S Deacock 1, W Turnbull 1, R Silvestrini 1, C Bunn 1, P White 1, M Ward 1
PMCID: PMC501075  PMID: 10450175

Abstract

AIMS: (1) To assess a range of intravenous immunoglobulin products for atypical classical antineutrophil cytoplasmic antibody (C-ANCA) staining and to determine if this is present in patients treated with high dose intravenous immunoglobulin (2 g/kg/month) and replacement doses (200 mg/kg fortnightly); (2) using the United Kingdom national external quality assessment scheme (NEQAS), to determine if laboratories could differentiate this pattern from classical ANCA. METHODS: ANCA testing was performed on 30 batches of intravenous immunoglobulin from several manufacturers. Six patients treated with high dose intravenous immunoglobulin and 11 receiving replacement doses of immunoglobulin for hypogammaglobulinaemia were tested for ANCA by indirect immunofluorescence on cytospin preparations of ethanol fixed neutrophils and by enzyme linked immunosorbent assay (ELISA). One of the positive immunoglobulin batches was tested blindly by 125 laboratories involved in NEQAS by indirect immunofluorescence and by ELISA in some laboratories. RESULTS: 16 of 31 batches of intravenous immunoglobulin from six different manufacturers were atypical C-ANCA positive. Three of six patients receiving high dose intravenous immunoglobulin and none of 11 patients on replacement doses were atypical C-ANCA positive. The results of the NEQAS assessment by indirect immunofluorescence were 68% C-ANCA positive, 17% negative, 9% atypical C-ANCA, and 6% P-ANCA. CONCLUSIONS: Some but not all intravenous immunoglobulin products yield a positive atypical cANCA by indirect immunofluorescence. An identical pattern may be observed in patients receiving high dose intravenous immunoglobulin but not in those on replacement doses. Of laboratories participating in NEQAS, 68% reported this pattern as cANCA. This reinforces the importance of reporting only "classical ANCA," defined by international ANCA workshops, to maintain the specificity of ANCA immunofluorescence and its close disease associations.

Full text

PDF
177

Images in this article

178Image
on p.178
179Image
on p.179
179Image
on p.179
179Image
on p.179

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayliffe W., Haeney M., Roberts S. C., Lavin M. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Lancet. 1992 Feb 29;339(8792):558–559. doi: 10.1016/0140-6736(92)90385-g. [DOI] [PubMed] [Google Scholar]
  2. Ben-Chetrit E., Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med. 1992 Jan 23;326(4):270–271. doi: 10.1056/NEJM199201233260413. [DOI] [PubMed] [Google Scholar]
  3. Dwyer J. M. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9;326(2):107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  4. Jennings J. G., Chang L., Savige J. A. Anti-proteinase 3 antibodies, their characterization and disease associations. Clin Exp Immunol. 1994 Feb;95(2):251–256. doi: 10.1111/j.1365-2249.1994.tb06519.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jolles S., Hughes J., Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol. 1998 Jan;134(1):80–86. doi: 10.1001/archderm.134.1.80. [DOI] [PubMed] [Google Scholar]
  6. Lassiter H. A., Bibb K. W., Bertolone S. J., Patel C. C., Stroncek D. F. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol. 1993 Feb;15(1):120–123. doi: 10.1097/00043426-199302000-00019. [DOI] [PubMed] [Google Scholar]
  7. Lock R. J. ACP Broadsheet No 143: January 1994. Detection of autoantibodies to neutrophil cytoplasmic antigens. J Clin Pathol. 1994 Jan;47(1):4–8. doi: 10.1136/jcp.47.1.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lockwood C. M. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol. 1996 May;104 (Suppl 1):77–82. [PubMed] [Google Scholar]
  9. Mouthon L., Kaveri S. V., Spalter S. H., Lacroix-Desmazes S., Lefranc C., Desai R., Kazatchkine M. D. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996 May;104 (Suppl 1):3–9. [PubMed] [Google Scholar]
  10. Rasmussen N., Wiik A. Indirect immunofluorescence examination for IgG-ANCA in sera submitted for the 1st international workshop on ANCA, 1988. APMIS Suppl. 1989;6:16–20. [PubMed] [Google Scholar]
  11. Roberts D. E. Antineutrophil cytoplasmic autoantibodies. Clin Lab Med. 1992 Mar;12(1):85–98. [PubMed] [Google Scholar]
  12. Rütter G. H. Requirements for safety and quality of intravenous immunoglobulin G preparations. J Neurol Neurosurg Psychiatry. 1994 Nov;57 (Suppl):2–5. doi: 10.1136/jnnp.57.suppl.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Savage C. O., Harper L., Adu D. Primary systemic vasculitis. Lancet. 1997 Feb 22;349(9051):553–558. doi: 10.1016/s0140-6736(97)80118-3. [DOI] [PubMed] [Google Scholar]
  14. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl. 1989;6:12–13. [PubMed] [Google Scholar]
  15. Zhao M. H., Jones S. J., Lockwood C. M. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol. 1995 Jan;99(1):49–56. doi: 10.1111/j.1365-2249.1995.tb03471.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES